

**Supplementary Table 1.** Modification of the recommendation of the 2019 EULAR guideline for the survey

Original	Modified
3. Patients with AIIRD should receive toxoid tetanus vaccination in accordance with recommendations for the general population. Passive immunisation should be considered for patients treated with B cell depleting therapy.	3a. Patients with AIIRD should receive toxoid tetanus vaccination in accordance with recommendations for the general population 3b. Passive immunisation should be considered for patients treated with B cell depleting therapy
4. Hepatitis A and hepatitis B vaccination should be administrated to patients with AIIRD at risk. In specific situations booster or passive immunisation is indicated.	4a. Hepatitis A and hepatitis B vaccination should be administrated to patients with AIIRD at risk 4b. In specific situations booster or passive immunisation of hepatitis A or hepatitis B is indicated.
9. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy.	9. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy 9a. Bacillus Calmette–Guérin (BCG) should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy

EULAR: European Alliance of Associations for Rheumatology, AIIRD: autoimmune inflammatory rheumatic diseases.

**Supplementary Table 2.** Agreement with and implementation of the principles and recommendations of 2019 EULAR guideline by regions

Overarching principles	Asia	North America	Europe	p-value
#1. Agreement	4.1±0.9	4.4±0.9	4.1±0.9	0.006*
#1. Implementation	3.3±1.1	3.7±1.1	3.5±1.3	0.001*
#2. Agreement	4.0±0.9	4.3±0.9	4.3±1.0	0.077
#2. Implementation	3.2±1.1	3.7±1.1	3.5±1.3	0.001*
#3. Agreement	4.1±0.9	3.7±1.1	4.2±1.0	0.001*
#3. Implementation	3.7±1.0	3.5±1.1	3.7±1.0	0.253
#4. Agreement	4.4±0.7	4.5±0.8	4.6±0.5	0.303
#4. Implementation	3.7±1.1	3.9±1.1	4.2±0.8	0.014*
#5. Agreement	4.4±0.9	4.4±0.8	4.5±0.7	0.901
#5. Implementation	4.2±1.1	4.4±0.8	4.3±0.9	0.129
#6. Agreement	3.7±1.2	3.4±1.3	3.6±1.1	0.169
#6. Implementation	3.3±1.4	3.2±1.3	3.4±1.4	0.811
<b>Recommendations</b>				
#1. Agreement	4.7±0.7	4.9±0.4	4.5±0.6	0.001*
#1. Implementation	4.4±0.9	4.8±0.6	4.3±0.8	0.000*
#2. Agreement	4.5±0.8	4.7±0.6	4.5±0.7	0.014*
#2. Implementation	4.0±0.9	4.4±0.9	4.1±1.1	0.001*
#3a. Agreement	3.8±1.1	4.6±0.7	4.4±0.8	0.000*
#3a. Implementation	2.8±1.2	3.9±1.3	3.7±1.2	0.000*
#3b. Agreement	3.5±1.0	3.2±1.2	3.2±0.9	0.003*
#3b. Implementation	2.9±1.2	2.6±1.3	2.7±1.1	0.226
#4a. Agreement	3.8±1.1	4.0±1.0	4.2±0.8	0.103
#4a. Implementation	3.1±1.4	3.1±1.4	3.4±1.3	0.280
#4b. Agreement	3.5±1.0	3.6±1.0	3.9±1.0	0.087*
#4b. Implementation	2.7±1.3	2.9±1.3	3.1±1.3	0.098*
#5. Agreement	4.1±1.1	4.7±0.6	3.9±0.9	0.000*
#5. Implementation	2.9±1.4	4.2±1.0	3.1±1.2	0.000*
#6. Agreement	3.4±1.3	3.7±1.3	3.5±1.3	0.121
#6. Implementation	2.9±1.5	3.5±1.4	3.2±1.4	0.004*
#7. Agreement	3.7±1.1	4.4±0.9	4.4±0.6	0.000*
#7. Implementation	2.6±1.3	3.3±1.5	3.6±1.2	0.000*
#8. Agreement	3.8±1.0	4.5±0.8	4.2±0.8	0.000*
#8. Implementation	2.8±1.4	3.5±1.4	3.3±1.2	0.000*
#9. Agreement	4.0±1.1	4.0±1.1	4.1±0.9	0.865
#9. Implementation	3.5±1.5	3.5±1.4	3.5±1.3	0.997
#9a. Agreement	3.9±1.1	3.9±1.1	3.9±1.0	0.943
#9a. Implementation	3.3±1.4	3.4±1.4	3.4±1.3	0.994

Values are presented as mean±standard deviation. Agreement: 1=strongly disagree; 5=strongly agree. Practice: 1=not at all; 5=all the time. EULAR: European Alliance of Associations for Rheumatology. \*p-values were generated by ANOVA.